Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis

@article{Su2002EfficacyOA,
  title={Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis},
  author={Chinyu G. Su and Bruce A. Salzberg and James D Lewis and Julius J. Deren and Asher A Kornbluth and David A Katzka and Robert Benjamin Stein and Douglas R Adler and Gary R Lichtenstein},
  journal={American Journal of Gastroenterology},
  year={2002},
  volume={97},
  pages={2577-2584}
}
OBJECTIVES:Tumor necrosis factor-α (TNF-α) is an important cytokine involved in the pathogenesis of inflammatory bowel disease. The monoclonal antibody to TNF-α, infliximab, is effective in treating Crohn's disease. Preclinical studies suggest the importance of TNF-α in treating ulcerative colitis (UC). We report the effectiveness of infliximab for UC and examine factors predictive of response to medication.METHODS:Data from all UC patients receiving infliximab at four institutions were… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 51 CITATIONS, ESTIMATED 52% COVERAGE

Infliximab in the treatment of severe ulcerative colitis.

  • Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva
  • 2004
VIEW 4 EXCERPTS
CITES RESULTS & BACKGROUND
HIGHLY INFLUENCED

Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.

  • BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
  • 2002
VIEW 5 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

Steroid Receptor Coactivator-Interacting Protein (SIP) Suppresses Myocardial Injury Caused by Acute Pancreatitis

  • Medical science monitor : international medical journal of experimental and clinical research
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

FILTER CITATIONS BY YEAR

2002
2018

CITATION STATISTICS

  • 3 Highly Influenced Citations

References

Publications referenced by this paper.
SHOWING 1-10 OF 31 REFERENCES

An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis.

  • The American journal of gastroenterology
  • 2001
VIEW 7 EXCERPTS
HIGHLY INFLUENTIAL

Mainte - nance infliximab ( Remicade ) is safe , effective and steroidsparing in Crohn ’ s disease : Preliminary results from the ACCENT I trial

SB Hanauer, GR Lichtenstein, Columbel J-F
  • Gastroenterology
  • 2001